Restoring Klf9 Expression with Pressure Overload Leads to Metabolic Maladaptation and Early Onset of Heart Failure

Q: What is the clinical evidence from this study?

Population: Cardiac hypertrophy and heart failure. Intervention: Restoration of Klf9 expression (conditional Klf9 knock-in) vs. Sham-operated and wild-type (MCM) control mice. Primary outcome: Development of cardiac hypertrophy and early-onset heart failure.

Aishwarya Venkatasubramanian; Chandni S. Thakkar; Z L Yang; Andreas Ivessa; Nazish Sayed; Maha Abdellatif; Danish H Sayed

doi:10.64898/2026.07.23.740419

July 24, 2026Open Access

Restoring Klf9 Expression with Pressure Overload Leads to Metabolic Maladaptation and Early Onset of Heart Failure

View Full Paper

Ask AI

Bookmark

Share

Key result

Restoring Klf9 initially curbs hypertrophy but disrupts cardiac metabolism, accelerating early-onset heart failure.

Why the study?

No studies have examined Klf9 transcriptional targets or its role in the progression of cardiac hypertrophy despite its decreased levels during hypertrophy.

Does restoring Klf9 expression improve or worsen pressure overload-induced cardiac hypertrophy and heart failure in mice?

Key Points

To identify genome-wide transcriptional targets of Klf9 during cardiac hypertrophy and determine the functional consequences of restoring Klf9 expression under pressure overload.
Profiled genome-wide Klf9 promoter occupancy using chromatin immunoprecipitation sequencing in hearts from mice subjected to sham or transaortic constriction (TAC) surgery for 2 weeks.
Subjected tamoxifen-inducible conditional Klf9 knock-in (Klf9KI) mice to sham or TAC operations for 1 or 2 weeks to evaluate cardiac remodeling.
ChIP-seq identified 4655 Klf9 intervals across 6309 genes in sham hearts and 4121 intervals across 5675 genes in TAC hearts, with 87.09% and 86.9% located in promoter regions, respectively.
TAC hearts exhibited 1167 merged regions with reduced Klf9 binding (log2FC ≤ 0.1) predominantly enriched for metabolic pathways, compared to 499 regions with increased occupancy.
Inducing a 3- to 5-fold increase in Klf9 transcript levels to normalize protein expression initially suppressed hypertrophy but led to early-onset heart failure.

Structured PICO

Does restoring Klf9 expression improve or worsen pressure overload-induced cardiac hypertrophy and heart failure in mice?

P

Population

A preclinical study utilizing conditional Klf9 knock-in mice subjected to transaortic constriction for 1 to 2 weeks to evaluate the role of Klf9 in cardiac hypertrophy.

I

Intervention

Restoring Klf9 expression via tamoxifen induction, followed by pressure overload induced by transaortic constriction (TAC) for 1 or 2 weeks

C

Comparator

Sham-operated mice and MCM control mice subjected to TAC

O

Outcome

Development of cardiac hypertrophy and early-onset heart failure (measured by left ventricular internal dimensions, ejection fraction, fractional shortening, and wall thickness)surrogate

A physiological decrease in Klf9 is required for metabolic adaptations during compensatory cardiac hypertrophy; maintaining high levels leads to metabolic maladaptation and early-onset heart failure.

Limitations

The study utilized a pressure overload (TAC) model, which may yield different findings compared to neurohormonal stressor models (like Angiotensin II) used in previous studies.
The precise upstream regulators of dynamic Klf9 expression changes during hypertrophy remain to be fully characterized in adult hearts.

Implication

Restoring Klf9 may accelerate heart failure despite initial hypertrophy suppression; hypothesis-generating for metabolic targets in human pressure-overload remodeling.

Abstract

Klf9 is a cardiac-enriched transcription factor of the Krüppel-like factor (Klf) family. Klf9 levels decrease during cardiac hypertrophy; however, no studies have examined its transcriptional targets or role in the progression of hypertrophy. Here, we report genome-wide differential Klf9 occupancy during cardiac hypertrophy, with a predominant enrichment at the metabolic gene promoters. Further, using conditional Klf9 knock-in mice subjected to pressure overload for 1 or 2 weeks, we show that restoring Klf9 expression initially inhibits hypertrophy but later leads to early-onset heart failure. We conclude that a decrease in Klf9 is required for metabolic adaptations that support the development of compensatory hypertrophy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Venkatasubramanian et al. (2026) studied Cardiac hypertrophy and heart failure. Restoration of Klf9 expression (conditional Klf9 knock-in) vs. Sham-operated and wild-type (MCM) control mice was evaluated on Development of cardiac hypertrophy and early-onset heart failure. Restoring Klf9 expression during pressure overload initially inhibits cardiac hypertrophy but subsequently disrupts metabolic adaptations and leads to early-onset heart failure.

synapsesocial.com/papers/6ad0fc2515427f6a8403ff92 https://doi.org/10.64898/2026.07.23.740419

View Full Paper

Ask AI

Bookmark

Share

Restoring Klf9 Expression with Pressure Overload Leads to Metabolic Maladaptation and Early Onset of Heart Failure

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Restoring Klf9 Expression with Pressure Overload Leads to Metabolic Maladaptation and Early Onset of Heart Failure

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading